Gabelli Equity Trust (GAB) 5.66 $GAB Fitch Affirms

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gabelli Equity Trust (GAB) 5.66 $GAB

Fitch Affirms Gabelli Fund Auction Preferred Ratings at 'AA'
BusinessWire - Tue Jun 21, 3:50PM CDT
Fitch Ratings has affirmed the 'AA' ratings assigned to the outstanding auction rate preferred shares of the four Gabelli equity closed-end funds listed below. All funds are managed by Gabelli Funds, LLC as investment adviser.
GGT: 7.37 (+0.01), GAB: 5.66 (unch), GBL: 32.08 (-1.56), GDV: 19.65 (+0.04), GUT: 6.68 (+0.05)

Gabelli Equity Trust Reaffirms Its 10% Distribution Policy and Declares Second Quarter Distribution of $0.15 Per Share
BusinessWire - Thu May 19, 8:14AM CDT
The Board of Directors of The Gabelli Equity Trust Inc. (NYSE:GAB) (the "Fund" reaffirmed its 10% distribution policy and declared a $0.15 per share cash distribution payable on June 23, 2016 to common stock shareholders of record on June 16, 2016.
GAB: 5.66 (unch), GBL: 32.08 (-1.56)

Gabelli Equity Trust Announces the Offering of $80 Million of 5.45% Series J Cumulative Preferred Stock
BusinessWire - Mon Mar 28, 3:35PM CDT
The Board of Directors of The Gabelli Equity Trust Inc. (NYSE:GAB) (the "Fund" is pleased to announce the completion of an offering of 3.2 million shares of 5.45% Series J Cumulative Preferred Stock ("Series J Preferred" valued at $80 million. The offering is expected to close on Thursday, March 31, 2016, subject to customary closing conditions.
GAB: 5.66 (unch), GBL: 32.08 (-1.56)

Gabelli Equity Trust Down 14.4% Since SmarTrend Downtrend Call (GAB)
Comtex SmarTrend(R) - Tue Jan 05, 11:58AM CST
SmarTrend identified a Downtrend for Gabelli Equity Trust (NYSE:GAB) on July 27th, 2015 at $6.09. In approximately 5 months, Gabelli Equity Trust has returned 14.45% as of today's recent price of $5.21.
GAB: 5.66 (unch)

Gabelli Equity Trust Shares Down 12.2% Since SmarTrend's Sell Call (GAB)
Comtex SmarTrend(R) - Thu Dec 24, 5:24PM CST
SmarTrend identified a Downtrend for Gabelli Equity Trust (NYSE:GAB) on July 27th, 2015 at $6.09. In approximately 5 months, Gabelli Equity Trust has returned 12.15% as of today's recent price of $5.35.
GAB: 5.66 (unch)

Shares of GAB Down 13.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Dec 17, 10:19AM CST
SmarTrend identified a Downtrend for Gabelli Equity Trust (NYSE:GAB) on July 27th, 2015 at $6.09. In approximately 5 months, Gabelli Equity Trust has returned 13.59% as of today's recent price of $5.26.
GAB: 5.66 (unch)

Gabelli Equity Trust Reaffirms Its 10% Distribution Policy and Declares Fourth Quarter Distribution of $0.19 Per Share
BusinessWire - Thu Nov 19, 3:05PM CST
The Board of Directors of The Gabelli Equity Trust Inc. (NYSE:GAB) (the "Fund" reaffirmed and satisfied its 10% distribution policy by declaring a $0.19 per share cash distribution payable on December 18, 2015 to common stock shareholders of record on December 11, 2015. With this fourth quarter distribution, the total distributions from the Fund for 2015 would equate to $0.64 per share. The Fund paid distributions of $0.15 per share in each of the first, second, and third quarters of 2015.
GAB: 5.66 (unch), GBL: 32.08 (-1.56)

Gabelli Equity Trust Has Returned 10.7% Since SmarTrend Recommendation (GAB)
Comtex SmarTrend(R) - Mon Nov 16, 10:10AM CST
SmarTrend identified a Downtrend for Gabelli Equity Trust (NYSE:GAB) on July 27th, 2015 at $6.09. In approximately 4 months, Gabelli Equity Trust has returned 10.67% as of today's recent price of $5.44.
GAB: 5.66 (unch)

7.9% Return Seen to Date on SmarTrend Gabelli Equity Trust Call (GAB)
Comtex SmarTrend(R) - Thu Oct 22, 9:42AM CDT
SmarTrend identified a Downtrend for Gabelli Equity Trust (NYSE:GAB) on July 27th, 2015 at $6.09. In approximately 3 months, Gabelli Equity Trust has returned 7.88% as of today's recent price of $5.61.
GAB: 5.66 (unch)

Gabelli Equity Trust Has Returned 7.8% Since SmarTrend Recommendation (GAB)
Comtex SmarTrend(R) - Fri Oct 09, 10:25AM CDT
SmarTrend identified a Downtrend for Gabelli Equity Trust (NYSE:GAB) on July 27th, 2015 at $6.09. In approximately 2 months, Gabelli Equity Trust has returned 7.78% as of today's recent price of $5.62.
GAB: 5.66 (unch)

11.8% Return Seen to Date on SmarTrend Gabelli Equity Trust Call (GAB)
Comtex SmarTrend(R) - Tue Sep 15, 10:14AM CDT
SmarTrend identified a Downtrend for Gabelli Equity Trust (NYSE:GAB) on July 27th, 2015 at $6.09. In approximately 2 months, Gabelli Equity Trust has returned 11.82% as of today's recent price of $5.37.
GAB: 5.66 (unch)

Gabelli Equity Trust Reaffirms Its 10% Distribution Policy and Declares Third Quarter Distribution of $0.15 Per Share
BusinessWire - Thu Aug 20, 8:26AM CDT
The Board of Directors of The Gabelli Equity Trust Inc. (NYSE:GAB) (the "Fund" reaffirmed its 10% distribution policy and declared a $0.15 per share cash distribution payable on September 23, 2015 to common stock shareholders of record on September 16, 2015.
GAB: 5.66 (unch), GBL: 32.08 (-1.56)

Gabelli Equity Trust Reaffirms Its 10% Distribution Policy and Declares First Quarter Distribution of $0.15 Per Share
BusinessWire - Tue Feb 17, 3:45PM CST
The Board of Directors of The Gabelli Equity Trust Inc. (NYSE:GAB) (the "Fund" reaffirmed its 10% distribution policy and declared a $0.15 per share cash distribution payable on March 24, 2015 to common stock shareholders of record on March 17, 2015.
GAB: 5.66 (unch), GBL: 32.08 (-1.56)

GAMCO Investors, Inc. Reports Fourth Quarter & Full Year Results
BusinessWire - Tue Feb 03, 4:30PM CST
--Second Best Fourth Quarter Earnings of $1.13 per diluted share
GAB: 5.66 (unch), GBL: 32.08 (-1.56)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
icles